Trials / Completed
CompletedNCT02595983
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.
Conditions
- Transthyretin (TTR)-Mediated Amyloidosis
- Familial Amyloidotic Polyneuropathy (FAP)
- ATTR Amyloidosis
- Familial Amyloid Neuropathies
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revusiran | 500mg Revusiran by subcutaneous (sc) injection |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-02-06
- Completion
- 2017-02-06
- First posted
- 2015-11-04
- Last updated
- 2019-03-28
- Results posted
- 2019-03-28
Locations
6 sites across 6 countries: France, Germany, Portugal, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02595983. Inclusion in this directory is not an endorsement.